TransMedics Group, Inc. (TMDX)
| Market Cap | 1.29B |
| Revenue (ttm) | 51.44M |
| Net Income (ttm) | -47.72M |
| Shares Out | 28.09M |
| EPS (ttm) | -1.69 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 694,274 |
| Open | 48.92 |
| Previous Close | 48.78 |
| Day's Range | 44.48 - 49.27 |
| 52-Week Range | 10.00 - 49.27 |
| Beta | 1.63 |
| Analysts | Buy |
| Price Target | 42.08 (-8.6%) |
| Earnings Date | Aug 1, 2022 |
About TMDX
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for dou... [Read more...]
Financial Performance
In 2021, TMDX's revenue was $30.26 million, an increase of 18.03% compared to the previous year's $25.64 million. Losses were -$44.22 million, 53.8% more than in 2020.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for TMDX stock is "Buy." The 12-month stock price forecast is 42.08, which is a decrease of -8.62% from the latest price.
News
TransMedics Announces Upsize and Pricing of Public Offering of Common Stock
ANDOVER, Mass. , Aug. 4, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-sta...
TransMedics Announces Proposed Public Offering of Common Stock
ANDOVER, Mass. , Aug. 3, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-sta...
TransMedics (TMDX) Reports Q2 Loss, Tops Revenue Estimates
TransMedics (TMDX) delivered earnings and revenue surprises of -28.13% and 26.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
TransMedics Reports Second Quarter 2022 Financial Results
Accelerated Commercial Momentum to Achieve Net Revenue of $20.5 million 2022 Revenue Guidance Range Raised to $67 million to $75 million ANDOVER, Mass. , Aug. 1, 2022 /PRNewswire/ -- TransMedics Group, ...
TransMedics to Present at the Canaccord Genuity 42nd Annual Growth Conference
ANDOVER, Mass. , July 26, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-st...
TransMedics to Report Second Quarter 2022 Financial Results on August 1, 2022
ANDOVER, Mass. , July 18, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-st...
Bear Market Winners: 3 Healthcare Stocks That Have Soared More Than 30% This Year
Have these scorching-hot stocks peaked, or could there still be more gains ahead for investors who buy today?
Up 1,000% in 5 Years? Here Are 3 Stocks That Can Run That High
Here's why our roundtable likes Intellia Therapeutics, Doximity, and TransMedics.
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANDOVER, Mass. , June 3, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-sta...
TransMedics Stock Skyrockets On Increased 2022 Guidance
TransMedics Group Inc (NASDAQ: TMDX) shares got a massive boost after better than expected Q1 earnings and 2022 guidance. The company posted an EPS loss of $(0.38) in line with expectations and higher t...
TransMedics (TMDX) Reports Q1 Loss, Tops Revenue Estimates
TransMedics (TMDX) delivered earnings and revenue surprises of -8.57% and 55.34%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
TransMedics Reports First Quarter 2022 Financial Results
ANDOVER, Mass. , May 3, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stag...
TransMedics Receives FDA PMA Approval of OCS™ DCD Heart Indication
ANDOVER, Mass. , April 28, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s...
TransMedics to Report First Quarter 2022 Financial Results on May 3, 2022
ANDOVER, Mass. , April 19, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s...
TransMedics Announces the Presentation of New OCS™ Heart and OCS™ Lung Clinical Data at the International Society of ...
ANDOVER, Mass., April 19, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-st...
TransMedics (TMDX) Soars 9.9%: Is Further Upside Left in the Stock?
TransMedics (TMDX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase i...
TransMedics to Present at the Oppenheimer's 32nd Annual Healthcare Conference
ANDOVER, Mass. , March 1, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-st...
TransMedics (TMDX) Reports Q4 Loss, Tops Revenue Estimates
TransMedics (TMDX) delivered earnings and revenue surprises of -6.98% and 26.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
TransMedics Reports Fourth Quarter and Full Year 2021 Financial Results
ANDOVER, Mass., Feb. 23, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-sta...
TransMedics to Present at the Cowen 42nd Annual Healthcare Conference
ANDOVER, Mass., Feb. 22, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-sta...
TransMedics to Report Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022
ANDOVER, Mass., Feb. 9, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stag...
TransMedics Announces Publication of OCS™ Liver PROTECT Trial Results in JAMA Surgery
ANDOVER, Mass., Jan. 5, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stag...
TransMedics to Present at the 40th Annual J.P. Morgan Healthcare Conference
ANDOVER, Mass. , Dec. 22, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-st...
TransMedics (TMDX) Reports Q3 Loss, Lags Revenue Estimates
TransMedics (TMDX) delivered earnings and revenue surprises of -46.88% and -30.50%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
TransMedics Reports Third Quarter 2021 Financial Results
ANDOVER, Mass., Nov. 9, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stag...